Zy Therapeutics

Zy TherapeuticsZy TherapeuticsZy Therapeutics

Zy Therapeutics

Zy TherapeuticsZy TherapeuticsZy Therapeutics
  • Home
  • About
  • The Problem
  • About BCDs
    • Sturge-Weber Syndrome
    • Tuberos Sclerosis
    • Neurocysticerosis
  • Our Solution
  • Who We Are
  • Corporate Communications
  • Contact Us
  • CTA
  • For Partners' Page
  • Publications
  • More
    • Home
    • About
    • The Problem
    • About BCDs
      • Sturge-Weber Syndrome
      • Tuberos Sclerosis
      • Neurocysticerosis
    • Our Solution
    • Who We Are
    • Corporate Communications
    • Contact Us
    • CTA
    • For Partners' Page
    • Publications
  • Home
  • About
  • The Problem
  • About BCDs
    • Sturge-Weber Syndrome
    • Tuberos Sclerosis
    • Neurocysticerosis
  • Our Solution
  • Who We Are
  • Corporate Communications
  • Contact Us
  • CTA
  • For Partners' Page
  • Publications

Kamini®: The First Therapy to Target Brain Calcification

  • ZY-001 (Kamini) is a reformulated version of  a reformulated version of disodium etidronate, optimized for brain delivery and improved bioavailability. Built on 40+ years of safe clinical use in bone and metabolic disease 
  • Orphan & Rare Pediatric Potential  
  • Pediatric and Adult populations 
  • Platform Extension (additional neuro disorders)
     

Timeline Visual

Zy Therapeutics

Copyright © 2025 Zy Therapeutics - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept